InsiderTrades.com logo
Amy L. Burroughs net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Amy Burroughs Biography and Net Worth

CEO of Terns Pharmaceuticals

Amy Burroughs joined as our Chief Executive Officer and a member of our Board of Directors in February 2024, bringing more than 25 years of leadership experience. Most recently, she served as CEO at Cleave Therapeutics, where she led the company through financings, spearheaded licensing and collaboration deals, and oversaw the clinical development of its investigational therapy, CB-5339, for the treatment of acute myeloid leukemia. Previously, she served as executive in residence at 5AM Ventures and, in parallel, as senior advisor to one of its portfolio companies, Crinetics Pharmaceuticals, during its initial public offering. Earlier in her career, Ms. Burroughs held roles of increasing responsibility in commercial and strategy at Genentech, commercial and business development at other high growth therapeutics companies, talent and governance at Egon Zehnder International, and brand management at Procter & Gamble. Ms. Burroughs earned her M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and her B.A. in computer science with a minor in economics from Dartmouth College. She is currently a member of the board and audit committees at Tenaya Therapeutics.

What is Amy L. Burroughs' net worth?

The estimated net worth of Amy L. Burroughs is at least $1.28 million as of June 25th, 2025. Burroughs owns 47,083 shares of Terns Pharmaceuticals stock worth more than $1,277,362 as of December 4th. This net worth evaluation does not reflect any other investments that Burroughs may own. Learn More about Amy L. Burroughs' net worth.

How old is Amy L. Burroughs?

Burroughs is currently 53 years old. There are 4 older executives and no younger executives at Terns Pharmaceuticals. Learn More on Amy L. Burroughs' age.

How do I contact Amy L. Burroughs?

The corporate mailing address for Burroughs and other Terns Pharmaceuticals executives is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. Terns Pharmaceuticals can also be reached via phone at 650-525-5535 and via email at [email protected]. Learn More on Amy L. Burroughs' contact information.

Has Amy L. Burroughs been buying or selling shares of Terns Pharmaceuticals?

Amy L. Burroughs has not been actively trading shares of Terns Pharmaceuticals during the last quarter. Most recently, on Wednesday, June 25th, Amy L. Burroughs bought 23,314 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $3.87 per share, with a total value of $90,225.18. Following the completion of the transaction, the chief executive officer now directly owns 47,083 shares of the company's stock, valued at $182,211.21. Learn More on Amy L. Burroughs' trading history.

Who are Terns Pharmaceuticals' active insiders?

Terns Pharmaceuticals' insider roster includes Amy Burroughs (CEO), Andrew Gengos (CFO), Melita Jung (Insider), Emil Kuriakose (Insider), Hongbo Lu (Director), and Jill Quigley (Director). Learn More on Terns Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Terns Pharmaceuticals?

In the last year, Terns Pharmaceuticals insiders bought shares 5 times. They purchased a total of 63,764 shares worth more than $297,042.68. In the last year, insiders at the sold shares 9 times. They sold a total of 63,938 shares worth more than $665,822.98. The most recent insider tranaction occured on November, 4th when Director Jill M Quigley sold 24,520 shares worth more than $441,360.00. Insiders at Terns Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Terns Pharmaceuticals.

Information on this page was last updated on 11/4/2025.

Amy L. Burroughs Insider Trading History at Terns Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/25/2025Buy23,314$3.87$90,225.1847,083View SEC Filing Icon  
12/5/2024Buy15,450$7.15$110,467.5019,099View SEC Filing Icon  
11/30/2024Buy510$5.11$2,606.1019,609View SEC Filing Icon  
See Full Table

Amy L. Burroughs Buying and Selling Activity at Terns Pharmaceuticals

This chart shows Amy L Burroughs's buying and selling at Terns Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Terns Pharmaceuticals Company Overview

Terns Pharmaceuticals logo
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $27.13
Low: $26.53
High: $28.17

50 Day Range

MA: $15.69
Low: $7.50
High: $29.34

2 Week Range

Now: $27.13
Low: $1.87
High: $29.51

Volume

3,624,545 shs

Average Volume

3,266,852 shs

Market Capitalization

$2.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A